Approval · Notice of Compliance 10013 · 2009
SOLIRIS: Notice of Compliance 10013
Issued January 28, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10013
- Date
- January 28, 2009
- Company
- Alexion Pharmaceuticals Inc
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Complement inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SOLIRIS | 02322285 | Marketed |
Medicinal ingredients
- ECULIZUMAB 10 MG per ML